In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor

T. Mikayama, I. Serizawa, M. Sato, T. Miura, T. Tomura, H. Watarai, N. Honma, N. Yuyama, M. Salo, Y. Takeuchi, N. Kubola, K. Ishizaka

Research output: Contribution to journalArticle

Abstract

We iiave previously described lhat suppressor T cell (Ts)-derivcd glycosylation inhibiting factor (GIF), a 13 kDa cylokine, suppressed in vivo antibody response. Since accumulating evidence suggested that conformationa! transition is involved in the generation of bioactive GIF by Ts, we generated bioactive recombinanl human GIF (recGIF) derivatives by mutations. Administration of recGIF derivative to DNP-OVA immunized BDFI mice resulted in suppression of the anti-DNP antibody response in a dose-dependent manner. When the recGIF was administered at the T cell priming with urea-denatured OVA, the anti-DNP antibody response to a booster injection of DNP-OVA was markedly suppressed. It was also found that proliferalive responses of splenic CD4F cells of OVA-primed mice to OVA was suppressed by the treatment of the donor with the recGIF at the priming immunization. The recGIF treatment at Oie time of a booster injection of DNP-OVA could not prevent the induction of anti-DNP antibody response but enhanced decline of the antibody tiler, and suppressed the antibody response to the next immunization of the same antigen. These results indicate that the in vivo immunosuppresive effects of GIF may be due not only to the inhibition of antigen-priming of T cells but also to Ihe induction of active suppression in the presence of antigen. When nonobase diabetic (NOD) mice were treated from 5 weeks of age with the recGIF, spontaneous diabetes was almost completely prpiccted. These results collectively suggest the possible approaches to the utilization of the recGIF derivtives for therapeutic purposes.

Original languageEnglish (US)
JournalFASEB Journal
Volume10
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

immunosuppression
glycosylation
Immunosuppression
chemical derivatives
Antibody Formation
Derivatives
T-cells
Antibodies
antibodies
Immunization
Anti-Idiotypic Antibodies
T-Lymphocytes
T-lymphocytes
Antigens
antigens
mice
immunization
Injections
injection
suppressor cells

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Mikayama, T., Serizawa, I., Sato, M., Miura, T., Tomura, T., Watarai, H., ... Ishizaka, K. (1996). In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor. FASEB Journal, 10(6).

In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor. / Mikayama, T.; Serizawa, I.; Sato, M.; Miura, T.; Tomura, T.; Watarai, H.; Honma, N.; Yuyama, N.; Salo, M.; Takeuchi, Y.; Kubola, N.; Ishizaka, K.

In: FASEB Journal, Vol. 10, No. 6, 1996.

Research output: Contribution to journalArticle

Mikayama, T, Serizawa, I, Sato, M, Miura, T, Tomura, T, Watarai, H, Honma, N, Yuyama, N, Salo, M, Takeuchi, Y, Kubola, N & Ishizaka, K 1996, 'In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor', FASEB Journal, vol. 10, no. 6.
Mikayama T, Serizawa I, Sato M, Miura T, Tomura T, Watarai H et al. In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor. FASEB Journal. 1996;10(6).
Mikayama, T. ; Serizawa, I. ; Sato, M. ; Miura, T. ; Tomura, T. ; Watarai, H. ; Honma, N. ; Yuyama, N. ; Salo, M. ; Takeuchi, Y. ; Kubola, N. ; Ishizaka, K. / In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor. In: FASEB Journal. 1996 ; Vol. 10, No. 6.
@article{f56914ec66494b4d93bb8b41db5eff79,
title = "In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor",
abstract = "We iiave previously described lhat suppressor T cell (Ts)-derivcd glycosylation inhibiting factor (GIF), a 13 kDa cylokine, suppressed in vivo antibody response. Since accumulating evidence suggested that conformationa! transition is involved in the generation of bioactive GIF by Ts, we generated bioactive recombinanl human GIF (recGIF) derivatives by mutations. Administration of recGIF derivative to DNP-OVA immunized BDFI mice resulted in suppression of the anti-DNP antibody response in a dose-dependent manner. When the recGIF was administered at the T cell priming with urea-denatured OVA, the anti-DNP antibody response to a booster injection of DNP-OVA was markedly suppressed. It was also found that proliferalive responses of splenic CD4F cells of OVA-primed mice to OVA was suppressed by the treatment of the donor with the recGIF at the priming immunization. The recGIF treatment at Oie time of a booster injection of DNP-OVA could not prevent the induction of anti-DNP antibody response but enhanced decline of the antibody tiler, and suppressed the antibody response to the next immunization of the same antigen. These results indicate that the in vivo immunosuppresive effects of GIF may be due not only to the inhibition of antigen-priming of T cells but also to Ihe induction of active suppression in the presence of antigen. When nonobase diabetic (NOD) mice were treated from 5 weeks of age with the recGIF, spontaneous diabetes was almost completely prpiccted. These results collectively suggest the possible approaches to the utilization of the recGIF derivtives for therapeutic purposes.",
author = "T. Mikayama and I. Serizawa and M. Sato and T. Miura and T. Tomura and H. Watarai and N. Honma and N. Yuyama and M. Salo and Y. Takeuchi and N. Kubola and K. Ishizaka",
year = "1996",
language = "English (US)",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - In vivo immunosuppression by derivatives of recombinant glycosylation inhibiting factor

AU - Mikayama, T.

AU - Serizawa, I.

AU - Sato, M.

AU - Miura, T.

AU - Tomura, T.

AU - Watarai, H.

AU - Honma, N.

AU - Yuyama, N.

AU - Salo, M.

AU - Takeuchi, Y.

AU - Kubola, N.

AU - Ishizaka, K.

PY - 1996

Y1 - 1996

N2 - We iiave previously described lhat suppressor T cell (Ts)-derivcd glycosylation inhibiting factor (GIF), a 13 kDa cylokine, suppressed in vivo antibody response. Since accumulating evidence suggested that conformationa! transition is involved in the generation of bioactive GIF by Ts, we generated bioactive recombinanl human GIF (recGIF) derivatives by mutations. Administration of recGIF derivative to DNP-OVA immunized BDFI mice resulted in suppression of the anti-DNP antibody response in a dose-dependent manner. When the recGIF was administered at the T cell priming with urea-denatured OVA, the anti-DNP antibody response to a booster injection of DNP-OVA was markedly suppressed. It was also found that proliferalive responses of splenic CD4F cells of OVA-primed mice to OVA was suppressed by the treatment of the donor with the recGIF at the priming immunization. The recGIF treatment at Oie time of a booster injection of DNP-OVA could not prevent the induction of anti-DNP antibody response but enhanced decline of the antibody tiler, and suppressed the antibody response to the next immunization of the same antigen. These results indicate that the in vivo immunosuppresive effects of GIF may be due not only to the inhibition of antigen-priming of T cells but also to Ihe induction of active suppression in the presence of antigen. When nonobase diabetic (NOD) mice were treated from 5 weeks of age with the recGIF, spontaneous diabetes was almost completely prpiccted. These results collectively suggest the possible approaches to the utilization of the recGIF derivtives for therapeutic purposes.

AB - We iiave previously described lhat suppressor T cell (Ts)-derivcd glycosylation inhibiting factor (GIF), a 13 kDa cylokine, suppressed in vivo antibody response. Since accumulating evidence suggested that conformationa! transition is involved in the generation of bioactive GIF by Ts, we generated bioactive recombinanl human GIF (recGIF) derivatives by mutations. Administration of recGIF derivative to DNP-OVA immunized BDFI mice resulted in suppression of the anti-DNP antibody response in a dose-dependent manner. When the recGIF was administered at the T cell priming with urea-denatured OVA, the anti-DNP antibody response to a booster injection of DNP-OVA was markedly suppressed. It was also found that proliferalive responses of splenic CD4F cells of OVA-primed mice to OVA was suppressed by the treatment of the donor with the recGIF at the priming immunization. The recGIF treatment at Oie time of a booster injection of DNP-OVA could not prevent the induction of anti-DNP antibody response but enhanced decline of the antibody tiler, and suppressed the antibody response to the next immunization of the same antigen. These results indicate that the in vivo immunosuppresive effects of GIF may be due not only to the inhibition of antigen-priming of T cells but also to Ihe induction of active suppression in the presence of antigen. When nonobase diabetic (NOD) mice were treated from 5 weeks of age with the recGIF, spontaneous diabetes was almost completely prpiccted. These results collectively suggest the possible approaches to the utilization of the recGIF derivtives for therapeutic purposes.

UR - http://www.scopus.com/inward/record.url?scp=33749114527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749114527&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749114527

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -